Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab’s antibody platforms power blockbuster drugs and an expansive oncology pipeline—but their SEC disclosures can stretch past 250 pages and dozens of exhibits. Finding where R&D spend shifts, or spotting when executives file Genmab insider trading Form 4 transactions, is challenging when every quarter brings new clinical data and collaboration milestones.
Stock Titan’s AI solves that problem. Our engine reads each Genmab quarterly earnings report 10-Q filing, highlights royalty streams from Darzalex and Tecvayli, and translates accounting footnotes into plain language. You’ll see
- Real-time alerts the moment a Genmab Form 4 insider transactions real-time record hits EDGAR.
- Concise explanations of 8-K material events—drug approvals, trial pauses, or amended AbbVie contracts—so Genmab 8-K material events explained makes sense in minutes.
- Side-by-side comparisons of cash burn across quarters to support your Genmab earnings report filing analysis.
Wondering about equity grants to management? The DEF 14A Genmab proxy statement executive compensation section is automatically summarised, while our dashboards track Genmab executive stock transactions Form 4 against upcoming catalyst dates. Need the big picture? Our AI creates a one-page brief titled Genmab annual report 10-K simplified so you can understand pipeline risks, patent cliffs, and royalty waterfalls without wading through technical jargon. For new investors asking, “How do I start understanding Genmab SEC documents with AI?”—this page is the starting point.
Genmab’s H1-25 6-K shows solid growth and an upgraded FY-25 outlook. Revenue climbed 19 % YoY to $1.64 bn on stronger DARZALEX (+22 % J&J sales), Kesimpta and EPKINLY. Royalty income rose 24 % to $1.38 bn, representing 84 % of total revenue. Operating profit increased 56 % to $548 m as costs grew only 6 %, expanding the margin to 33 %. Net profit reached $531 m.
Liquidity remains robust with $1.30 bn cash and $1.60 bn marketable securities; equity ratio is 82 %. Functional and presentation currency switched to USD on 1 Jan 25.
Revised 2025 guidance: revenue $3.5-3.7 bn (mid-point +$100 m), operating profit $1.055-1.405 bn (mid-point +$100 m); operating-expense range unchanged.
Operational highlights: sBLA filed for epcoritamab+R2 in r/r FL; Tivdak launched in Japan; Rina-S posted 50 % ORR in endometrial cancer; >40 epcoritamab abstracts presented. Workforce up to 2,639 FTEs.
Risks & negatives: TEPEZZA royalties -8 %; lower reimbursement revenue; ongoing Chugai patent suit and AbbVie trade-secret litigation; FX gains moderated after USD switch.
Genmab A/S has filed a Form 6-K reporting transactions related to its ongoing share buy-back program for the period of June 16-20, 2025. The filing includes two key exhibits:
- A company announcement dated June 23, 2025, detailing transactions connected to the share buy-back program
- An appendix providing specific details of the share buyback program's execution for the week of June 16-20, 2025
The report was signed by Anthony Pagano, Executive Vice President & Chief Financial Officer. This Form 6-K will be incorporated by reference into Genmab's multiple S-8 registration statements (File Numbers: 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876). The company continues to file annual reports under Form 20-F as a foreign private issuer.
FAQ
What is the current stock price of Genmab (GMAB)?
What is the market cap of Genmab (GMAB)?
